Recognizing Cardiovascular Risks with Ibrutinib

Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. In years past, many patients lived only a few years after diagnosis, but with these therapies, survival can now extend two decades or more. This remarkable improvement in outcomes has also shifted the focus of care: patients are living long enough for clinicians to observe and manage the long-term consequences of therapy. With ibrutinib, the first-generation BTK inhibitor, adverse cardiovascular effects have become clear. This quiz highlights one of the most notable complications clinicians should monitor.

Reference
Lenihan D. Multidisciplinary management of cardiovascular risk in patients with CLL on BTK inhibitors. Consultant360. Accessed September 3, 2025. https://www.consultant360.com/qas/multidisciplinary-management-cardiovascular-risk-patients-cll-btk-inhibitors

©2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.